Literature DB >> 32717272

Combinatorial drug therapy in cancer - New insights.

Karanpreet Bhatia1, Asmita Das2.   

Abstract

Cancer can arise due to mutations in numerous pathways present in our body and thus has many alternatives for getting aggravated. Due to this attribute, it gets difficult to treat cancer patients with monotherapy alone and has a risk of not being eliminated to the full extent. This necessitates the introduction of combinatorial therapy as it employs cancer treatment using more than one method and shows a greater success rate. Combinatorial therapy involves a complementary combination of two different therapies like a combination of radio and immunotherapy or a combination of drugs that can target more than one pathway of cancer formation like combining CDK targeting drugs with Growth factors targeting drugs. In this review, we discuss the various aspects of cancer which include, its causes; four regulatory mechanisms namely: apoptosis, cyclin-dependent kinases, tumor suppressor genes, and growth factors; some of the pathways involved; treatment: monotherapy and combinatorial therapy and combinatorial drug formulation in chemotherapy. The present review gives a holistic account of the different mechanisms of therapies and also drug combinations that may serve to not only complement the monotherapy but can also surpass the resistance against monotherapy agents.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32717272     DOI: 10.1016/j.lfs.2020.118134

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Dezocine Has the Potential to Regulate the Clinical and Biological Features of Tumors.

Authors:  Xudong Hu; Bing Luo; Lei Qiu; Shaosen Chen; Qing Wu; Qingbiao Chen; Xingqing Liu; Chen Ling; Shuping Deng; Manjuan Yuan; Peicun Hu
Journal:  Drug Des Devel Ther       Date:  2022-04-20       Impact factor: 4.319

2.  Injectable, Anti-Cancer Drug-Eluted Chitosan Microspheres against Osteosarcoma.

Authors:  Jiebing Zhao; Hao Tian; Fusheng Shang; Tao Lv; Dagui Chen; Jianjun Feng
Journal:  J Funct Biomater       Date:  2022-07-10

Review 3.  EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies.

Authors:  Ivana Samaržija; Marko Tomljanović; Renata Novak Kujundžić; Koraljka Gall Trošelj
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

Review 4.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 5.  Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice.

Authors:  Sabrina Orzetti; Federica Tommasi; Antonella Bertola; Giorgia Bortolin; Elisabetta Caccin; Sara Cecco; Emanuela Ferrarin; Elisa Giacomin; Paolo Baldo
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.